

INVITED CHAIRPEOPLE

Scientific Coordinator

Mario Cicardi, Italy

A. Banerji, USA

S. Bonini, Italy

K. Bork, Germany

L. Bouillet, France

P. Busse, USA

T. Caballero, Spain

T. Castaldo, USA

M. Cicardi, Italy

C. Federici, Italy

A. E. Germenis, Greece

A. Kaplan, USA

H. Longhurst, UK

W. Lumry, USA

C. Maas, The Netherlands

M. Maurer, Germany

F. Perego, Italy

M. Riedl, USA

A.H. Schmaier, USA

B. Zuraw, USA

A. Zanichelli, Italy

GENERAL INFORMATION

VENUE

Palazzo Feltrinelli
Via XIV Maggio, 18
25084 - Gargnano (BS)
ITALY

ACCOMODATION

Housing and meals will be provided to all participants.

ORGANIZING SECRETARIAT



Via Ciovasso 4 - 20121 Milano
Tel. +39 02 29534181 - Fax. +39 02 29532309
Email: laura.luraschi@tccompany.it
www.tccompany.it

TRAVEL

Sunday September 18th:

A bus transfer from Milan to Gargnano will depart from Milan Cadorna Station at 17.00 (5 pm CEST).

Cadorna Station is easily reachable from Milan Area Airports:

From Milan Malpensa

At terminal 1 please follow directions for "Malpensa Express". Take train direct to Stazione Nord Cadorna/Cadorna Station (Trains run every 30 minutes - 36 minutes ride).

From Milan Linate

Take bus no. 73 in the "National Arrivals Exit" area all the way to the terminal of Piazza San Babila. Go down into the Underground. Here take the Red Line M1 (direction Bisceglie) to Cadorna Station (4 stops).

On Wednesday September 21st:

GOING BACK HOME?

Bus Transfer to Milano Cadorna Station will depart at 9.00 am CEST from Gargnano and will arrive by noon.

GOING TO BERLIN?

Bus Transfer to Milan Bergamo Airport will depart at 6.00 am CEST from Gargnano.

For assistance or special needs, please contact Laura of the Organizing Secretariat.

PRELIMINARY PROGRAMME



TREATING PATIENTS WITH C1 INHIBITOR
HEREDITARY ANGIOEDEMA

THIRD HAWK CONSENSUS CONFERENCE

September 18th - 21st, 2016
Gargnano, Garda Lake
Palazzo Feltrinelli

SUNDAY SEPTEMBER 18th

Arrival

20:30 *Dinner*MONDAY SEPTEMBER 19th8:00 – 10:00 **SESSION 1****May C1 inhibitor deficiency or its treatment change the risk of developing pathologic conditions***Chairperson: Alvin H Schmaier - Francesca Perego - Nancy Brown*

Objective: Discuss rearrangements of the systems controlled by C1-INH to compensate its deficiency. Analyze whether this rearrangement or its therapeutic manipulation could modify the risk for developing pathologic conditions other than angioedema.

*Coffee Break*10:30 – 12:30 **SESSION 2****Clinical markers of disease severity in patients with C1-INH-HAE***Chairperson: Teresa Caballero - Marcus Maurer - Paula Busse - Anette Bygum*

Objective: Discuss the different strategies for quantifying the burden caused by C1-INH-HAE. Develop a proposal for a unique approach to monitor disease severity, guide clinical decisions and evaluate treatment efficacy.

*Lunch*14:00 – 16.30 **SESSION 3****Laboratory markers of disease severity in patients with C1-INH-HAE***Chairperson: Anastasios E. Germenis - Allen Kaplan - Coen Maas*

Objective: Discuss laboratory targets that could define disease severity. Identify established and potential value/limitation. Suggest a laboratory algorithm to diagnose and monitor patients with C1-INH-HAE.

*Coffee Break*16:30 – 18.30 **SESSION 4****Pharmacoeconomics of C1-INH-HAE***Chairperson: Tony Castaldo - Carlo Federici - William Lumry*

Objective: Discuss the tools for merging sustainable therapies into disease related suffering. Elaborate parameters to measure cost/benefit balance in patients with C1-INH-HAE.

20:00 *Dinner*TUESDAY SEPTEMBER 20th8:00 – 10:00 **SESSION 5****Disease modifying strategies in C1-INH-HAE***Chairperson: Mark Riedl - Konrad Bork - Hilary Longhurst*

Objective: Discuss on demand versus prophylactic approach. Overlapping and discordant targets. Elaborate a strategy to drive their optimal use.

*Coffee Break*10:30 – 12.30 **SESSION 6****Minimizing adverse events related to therapies***Chairperson: Sergio Bonini - Timoty Craig - David Essayan - Massimo Triggiani*

Objective: Discuss the evaluation of potential adverse events of new therapies and how to plan an efficient post-marketing surveillance with the contribution of patients, physicians, companies and regulatory agencies. Elaborate on the creation of common registry fulfilling pharmacovigilance purposes.

*Lunch*14:00 – 16:00 **SESSION 7****Establishing a network of reference centers for C1-INH-HAE***Chairperson: Aleena Banerji - Laurence Bouillet - Andrea Zanichelli*

Objective: Discuss the requirements for reference centers and corresponding network. Elaborate on the creation of reference panel for accreditation.

*Coffee Break*16:30 – 18:30 **CONSENSUS***Chairperson: Bruce Zuraw - Marco Cicardi*20:00 *Dinner*WEDNESDAY SEPTEMBER 21st

Departure